^
Association details:
| Biomarker: | KRAS wild-type |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | TheraCIM (nimotuzumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
Published date:
08/30/2023
Excerpt:
Both OS and PFS were longer in the nimotuzumab group than in the placebo group. The objective response rates and disease control rates were 7% versus 10% and 68% versus 63% for the investigational and control groups, respectively….In patients with locally advanced or metastatic K-Ras wild-type PC, nimotuzumab plus gemcitabine significantly improved OS and PFS with a good safety profile.
Secondary therapy:
gemcitabine
DOI:
10.1200/JCO.22.02630
Trial ID:
